HROW Samsung Bioepis and Harrow Present Interim Data from a Large Scale Post Marketing Surveillance Study on SB11 (BYOOVIZ / AMELIVU), a Bio

HROW Samsung Bioepis and Harrow Present Interim Data from a Large Scale Post Marketing Surveillance Study on SB11 (BYOOVIZ / AMELIVU), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026